Immix Biopharma (IMMX) Share-based Compensation (2020 - 2026)

Immix Biopharma has reported Share-based Compensation for 6 years, with the latest figure at $508065.0 in Q1 2026.

• Quarterly Share-based Compensation rose 16.88% year-over-year to $508065.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 83.59% YoY) and the FY2025 annual result came in at $2.4 million, down 19.16% from the prior year.
• Share-based Compensation slipped to $508065.0 in Q1 2026 per IMMX's latest filing, from $2.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $2.4 million in Q4 2025 and troughed at $65074.0 in Q1 2022.
• A 5-year average of $552653.4 and a median of $441178.5 in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation jumped 1432.23% in 2022, then tumbled 74.46% in 2025.
• Over 5 years, Share-based Compensation stood at $130094.0 in 2022, then soared by 707.73% to $1.1 million in 2023, then sank by 32.85% to $705653.0 in 2024, then soared by 246.04% to $2.4 million in 2025, then sank by 79.19% to $508065.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $508065.0, $2.4 million, and $75046.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.